In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine

Abstract excerpt

Lamivudine therapy selects for the M184V mutation. Although this mutation reduces the replicative capacity of human immunodeficiency virus in vitro, its impact on viral fitness in vivo has not been well defined. We used quantitative allele-specific PCR to precisely calculate the fitness differences between the mutated M184V virus and one that had reverted to the wild type in a cohort of patients by selectively...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis C virus research
• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment